ID   AAPK2_HUMAN             Reviewed;         552 AA.
AC   P54646; Q9H1E8; Q9UD43;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2002, sequence version 2.
DT   10-MAY-2017, entry version 179.
DE   RecName: Full=5'-AMP-activated protein kinase catalytic subunit alpha-2;
DE            Short=AMPK subunit alpha-2;
DE            EC=2.7.11.1 {ECO:0000250|UniProtKB:Q09137};
DE   AltName: Full=Acetyl-CoA carboxylase kinase;
DE            Short=ACACA kinase;
DE            EC=2.7.11.27 {ECO:0000250|UniProtKB:Q09137};
DE   AltName: Full=Hydroxymethylglutaryl-CoA reductase kinase;
DE            Short=HMGCR kinase;
DE            EC=2.7.11.31 {ECO:0000250|UniProtKB:Q09137};
GN   Name=PRKAA2; Synonyms=AMPK, AMPK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Heart;
RX   PubMed=7959015; DOI=10.1016/0378-1119(94)90174-0;
RA   Aguan K., Scott J., See C.G., Sarkar N.H.;
RT   "Characterization and chromosomal localization of the human homologue
RT   of a rat AMP-activated protein kinase-encoding gene: a major regulator
RT   of lipid metabolism in mammals.";
RL   Gene 149:345-350(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skeletal muscle;
RX   PubMed=7988703; DOI=10.1016/0014-5793(94)01247-4;
RA   Beri R.K., Marley A.E., See C.G., Sopwith W.F., Aguan K., Carling D.,
RA   Scott J., Carey F.;
RT   "Molecular cloning, expression and chromosomal localisation of human
RT   AMP-activated protein kinase.";
RL   FEBS Lett. 356:117-121(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION.
RX   PubMed=11554766; DOI=10.1006/bbrc.2001.5627;
RA   Imamura K., Ogura T., Kishimoto A., Kaminishi M., Esumi H.;
RT   "Cell cycle regulation via p53 phosphorylation by a 5'-AMP activated
RT   protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-
RT   ribofuranoside, in a human hepatocellular carcinoma cell line.";
RL   Biochem. Biophys. Res. Commun. 287:562-567(2001).
RN   [6]
RP   FUNCTION IN PHOSPHORYLATION OF EP300.
RX   PubMed=11518699; DOI=10.1074/jbc.C100316200;
RA   Yang W., Hong Y.H., Shen X.Q., Frankowski C., Camp H.S., Leff T.;
RT   "Regulation of transcription by AMP-activated protein kinase:
RT   phosphorylation of p300 blocks its interaction with nuclear
RT   receptors.";
RL   J. Biol. Chem. 276:38341-38344(2001).
RN   [7]
RP   ENZYME REGULATION.
RX   PubMed=11602624; DOI=10.1172/JCI13505;
RA   Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M.,
RA   Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F.,
RA   Goodyear L.J., Moller D.E.;
RT   "Role of AMP-activated protein kinase in mechanism of metformin
RT   action.";
RL   J. Clin. Invest. 108:1167-1174(2001).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF CFTR.
RX   PubMed=12519745; DOI=10.1152/ajpcell.00227.2002;
RA   Hallows K.R., Kobinger G.P., Wilson J.M., Witters L.A., Foskett J.K.;
RT   "Physiological modulation of CFTR activity by AMP-activated protein
RT   kinase in polarized T84 cells.";
RL   Am. J. Physiol. 284:C1297-C1308(2003).
RN   [9]
RP   FUNCTION IN PHOSPHORYLATION OF TSC2.
RX   PubMed=14651849; DOI=10.1016/S0092-8674(03)00929-2;
RA   Inoki K., Zhu T., Guan K.L.;
RT   "TSC2 mediates cellular energy response to control cell growth and
RT   survival.";
RL   Cell 115:577-590(2003).
RN   [10]
RP   PHOSPHORYLATION AT THR-172, AND ENZYME REGULATION.
RX   PubMed=15980064; DOI=10.1074/jbc.M503824200;
RA   Hurley R.L., Anderson K.A., Franzone J.M., Kemp B.E., Means A.R.,
RA   Witters L.A.;
RT   "The Ca2+/calmodulin-dependent protein kinase kinases are AMP-
RT   activated protein kinase kinases.";
RL   J. Biol. Chem. 280:29060-29066(2005).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15866171; DOI=10.1016/j.molcel.2005.03.027;
RA   Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y.,
RA   Birnbaum M.J., Thompson C.B.;
RT   "AMP-activated protein kinase induces a p53-dependent metabolic
RT   checkpoint.";
RL   Mol. Cell 18:283-293(2005).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF FOXO3.
RX   PubMed=17711846; DOI=10.1074/jbc.M705325200;
RA   Greer E.L., Oskoui P.R., Banko M.R., Maniar J.M., Gygi M.P.,
RA   Gygi S.P., Brunet A.;
RT   "The energy sensor AMP-activated protein kinase directly regulates the
RT   mammalian FOXO3 transcription factor.";
RL   J. Biol. Chem. 282:30107-30119(2007).
RN   [13]
RP   FUNCTION IN CELL POLARITY.
RX   PubMed=17486097; DOI=10.1038/nature05828;
RA   Lee J.H., Koh H., Kim M., Kim Y., Lee S.Y., Karess R.E., Lee S.H.,
RA   Shong M., Kim J.M., Kim J., Chung J.;
RT   "Energy-dependent regulation of cell structure by AMP-activated
RT   protein kinase.";
RL   Nature 447:1017-1020(2007).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF HDAC5.
RX   PubMed=18184930; DOI=10.2337/db07-0843;
RA   McGee S.L., van Denderen B.J., Howlett K.F., Mollica J.,
RA   Schertzer J.D., Kemp B.E., Hargreaves M.;
RT   "AMP-activated protein kinase regulates GLUT4 transcription by
RT   phosphorylating histone deacetylase 5.";
RL   Diabetes 57:860-867(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   FUNCTION IN PHOSPHORYLATION OF KLC1.
RX   PubMed=20074060; DOI=10.1042/BST0380205;
RA   McDonald A., Fogarty S., Leclerc I., Hill E.V., Hardie D.G.,
RA   Rutter G.A.;
RT   "Cell-wide analysis of secretory granule dynamics in three dimensions
RT   in living pancreatic beta-cells: evidence against a role for AMPK-
RT   dependent phosphorylation of KLC1 at Ser517/Ser520 in glucose-
RT   stimulated insulin granule movement.";
RL   Biochem. Soc. Trans. 38:205-208(2010).
RN   [19]
RP   FUNCTION.
RX   PubMed=20160076; DOI=10.1073/pnas.0913860107;
RA   Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H.,
RA   Inoki K., Guan K.L., Shen J., Person M.D., Kusewitt D., Mills G.B.,
RA   Kastan M.B., Walker C.L.;
RT   "ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response
RT   to ROS.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:4153-4158(2010).
RN   [20]
RP   PHOSPHORYLATION BY ULK1.
RX   PubMed=21460634; DOI=10.4161/auto.7.7.15451;
RA   Loffler A.S., Alers S., Dieterle A.M., Keppeler H., Franz-Wachtel M.,
RA   Kundu M., Campbell D.G., Wesselborg S., Alessi D.R., Stork B.;
RT   "Ulk1-mediated phosphorylation of AMPK constitutes a negative
RT   regulatory feedback loop.";
RL   Autophagy 7:696-706(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   FUNCTION IN PHOSPHORYLATION OF ULK1.
RX   PubMed=21205641; DOI=10.1126/science.1196371;
RA   Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A.,
RA   Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M.,
RA   Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J.;
RT   "Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase
RT   connects energy sensing to mitophagy.";
RL   Science 331:456-461(2011).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=17307971; DOI=10.1161/01.RES.0000256090.42690.05;
RA   Towler M.C., Hardie D.G.;
RT   "AMP-activated protein kinase in metabolic control and insulin
RT   signaling.";
RL   Circ. Res. 100:328-341(2007).
RN   [24]
RP   REVIEW ON FUNCTION.
RX   PubMed=17712357; DOI=10.1038/nrm2249;
RA   Hardie D.G.;
RT   "AMP-activated/SNF1 protein kinases: conserved guardians of cellular
RT   energy.";
RL   Nat. Rev. Mol. Cell Biol. 8:774-785(2007).
RN   [25]
RP   ENZYME REGULATION BY SALICYLATE.
RX   PubMed=22517326; DOI=10.1126/science.1215327;
RA   Hawley S.A., Fullerton M.D., Ross F.A., Schertzer J.D., Chevtzoff C.,
RA   Walker K.J., Peggie M.W., Zibrova D., Green K.A., Mustard K.J.,
RA   Kemp B.E., Sakamoto K., Steinberg G.R., Hardie D.G.;
RT   "The ancient drug salicylate directly activates AMP-activated protein
RT   kinase.";
RL   Science 336:918-922(2012).
RN   [26]
RP   DEPHOSPHORYLATION AT THR-172.
RX   PubMed=23088624; DOI=10.1042/BJ20121201;
RA   Chida T., Ando M., Matsuki T., Masu Y., Nagaura Y.,
RA   Takano-Yamamoto T., Tamura S., Kobayashi T.;
RT   "N-Myristoylation is essential for protein phosphatases PPM1A and
RT   PPM1B to dephosphorylate their physiological substrates in cells.";
RL   Biochem. J. 449:741-749(2013).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-377, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=25687571; DOI=10.1074/mcp.M114.047159;
RA   Boutchueng-Djidjou M., Collard-Simard G., Fortier S., Hebert S.S.,
RA   Kelly I., Landry C.R., Faure R.L.;
RT   "The last enzyme of the de novo purine synthesis pathway 5-
RT   aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP
RT   cyclohydrolase (ATIC) plays a central role in insulin signaling and
RT   the Golgi/endosomes protein network.";
RL   Mol. Cell. Proteomics 14:1079-1092(2015).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 6-279.
RX   PubMed=20124709; DOI=10.1107/S1744309109052543;
RA   Littler D.R., Walker J.R., Davis T., Wybenga-Groot L.E.,
RA   Finerty P.J. Jr., Newman E., Mackenzie F., Dhe-Paganon S.;
RT   "A conserved mechanism of autoinhibition for the AMPK kinase domain:
RT   ATP-binding site and catalytic loop refolding as a means of
RT   regulation.";
RL   Acta Crystallogr. F 66:143-151(2010).
RN   [30]
RP   X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 6-279 OF MUTANT THR-172 IN
RP   COMPLEX WITH COMPOUND C, AND ENZYME REGULATION.
RX   PubMed=21543851; DOI=10.1107/S0907444911010201;
RA   Handa N., Takagi T., Saijo S., Kishishita S., Takaya D., Toyama M.,
RA   Terada T., Shirouzu M., Suzuki A., Lee S., Yamauchi T.,
RA   Okada-Iwabu M., Iwabu M., Kadowaki T., Minokoshi Y., Yokoyama S.;
RT   "Structural basis for compound C inhibition of the human AMP-activated
RT   protein kinase alpha2 subunit kinase domain.";
RL   Acta Crystallogr. D 67:480-487(2011).
RN   [31]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLY-523.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-371 AND GLN-407.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Catalytic subunit of AMP-activated protein kinase
CC       (AMPK), an energy sensor protein kinase that plays a key role in
CC       regulating cellular energy metabolism. In response to reduction of
CC       intracellular ATP levels, AMPK activates energy-producing pathways
CC       and inhibits energy-consuming processes: inhibits protein,
CC       carbohydrate and lipid biosynthesis, as well as cell growth and
CC       proliferation. AMPK acts via direct phosphorylation of metabolic
CC       enzymes, and by longer-term effects via phosphorylation of
CC       transcription regulators. Also acts as a regulator of cellular
CC       polarity by remodeling the actin cytoskeleton; probably by
CC       indirectly activating myosin. Regulates lipid synthesis by
CC       phosphorylating and inactivating lipid metabolic enzymes such as
CC       ACACA, ACACB, GYS1, HMGCR and LIPE; regulates fatty acid and
CC       cholesterol synthesis by phosphorylating acetyl-CoA carboxylase
CC       (ACACA and ACACB) and hormone-sensitive lipase (LIPE) enzymes,
CC       respectively. Regulates insulin-signaling and glycolysis by
CC       phosphorylating IRS1, PFKFB2 and PFKFB3. Involved in insulin
CC       receptor/INSR internalization (PubMed:25687571). AMPK stimulates
CC       glucose uptake in muscle by increasing the translocation of the
CC       glucose transporter SLC2A4/GLUT4 to the plasma membrane, possibly
CC       by mediating phosphorylation of TBC1D4/AS160. Regulates
CC       transcription and chromatin structure by phosphorylating
CC       transcription regulators involved in energy metabolism such as
CC       CRTC2/TORC2, FOXO3, histone H2B, HDAC5, MEF2C, MLXIPL/ChREBP,
CC       EP300, HNF4A, p53/TP53, SREBF1, SREBF2 and PPARGC1A. Acts as a key
CC       regulator of glucose homeostasis in liver by phosphorylating
CC       CRTC2/TORC2, leading to CRTC2/TORC2 sequestration in the
CC       cytoplasm. In response to stress, phosphorylates 'Ser-36' of
CC       histone H2B (H2BS36ph), leading to promote transcription. Acts as
CC       a key regulator of cell growth and proliferation by
CC       phosphorylating TSC2, RPTOR and ATG1/ULK1: in response to nutrient
CC       limitation, negatively regulates the mTORC1 complex by
CC       phosphorylating RPTOR component of the mTORC1 complex and by
CC       phosphorylating and activating TSC2. In response to nutrient
CC       limitation, promotes autophagy by phosphorylating and activating
CC       ATG1/ULK1. AMPK also acts as a regulator of circadian rhythm by
CC       mediating phosphorylation of CRY1, leading to destabilize it. May
CC       regulate the Wnt signaling pathway by phosphorylating CTNNB1,
CC       leading to stabilize it. Also phosphorylates CFTR, EEF2K, KLC1,
CC       NOS3 and SLC12A1. Plays an important role in the differential
CC       regulation of pro-autophagy (composed of PIK3C3, BECN1, PIK3R4 and
CC       UVRAG or ATG14) and non-autophagy (composed of PIK3C3, BECN1 and
CC       PIK3R4) complexes, in response to glucose starvation. Can inhibit
CC       the non-autophagy complex by phosphorylating PIK3C3 and can
CC       activate the pro-autophagy complex by phosphorylating BECN1 (By
CC       similarity). {ECO:0000250|UniProtKB:Q8BRK8,
CC       ECO:0000269|PubMed:11518699, ECO:0000269|PubMed:11554766,
CC       ECO:0000269|PubMed:12519745, ECO:0000269|PubMed:14651849,
CC       ECO:0000269|PubMed:15866171, ECO:0000269|PubMed:17486097,
CC       ECO:0000269|PubMed:17711846, ECO:0000269|PubMed:18184930,
CC       ECO:0000269|PubMed:20074060, ECO:0000269|PubMed:20160076,
CC       ECO:0000269|PubMed:21205641, ECO:0000269|PubMed:25687571,
CC       ECO:0000269|PubMed:7959015}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000250|UniProtKB:Q09137}.
CC   -!- CATALYTIC ACTIVITY: ATP + [acetyl-CoA carboxylase] = ADP +
CC       [acetyl-CoA carboxylase] phosphate.
CC       {ECO:0000250|UniProtKB:Q09137}.
CC   -!- CATALYTIC ACTIVITY: ATP + [hydroxymethylglutaryl-CoA reductase
CC       (NADPH)] = ADP + [hydroxymethylglutaryl-CoA reductase (NADPH)]
CC       phosphate. {ECO:0000250|UniProtKB:Q09137}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Activated by phosphorylation on Thr-172.
CC       Binding of AMP to non-catalytic gamma subunit (PRKAG1, PRKAG2 or
CC       PRKAG3) results in allosteric activation, inducing phosphorylation
CC       on Thr-172. AMP-binding to gamma subunit also sustains activity by
CC       preventing dephosphorylation of Thr-172. ADP also stimulates Thr-
CC       172 phosphorylation, without stimulating already phosphorylated
CC       AMPK. ATP promotes dephosphorylation of Thr-172, rendering the
CC       enzyme inactive. Under physiological conditions AMPK mainly exists
CC       in its inactive form in complex with ATP, which is much more
CC       abundant than AMP. AMPK is activated by antihyperglycemic drug
CC       metformin, a drug prescribed to patients with type 2 diabetes: in
CC       vivo, metformin seems to mainly inhibit liver gluconeogenesis.
CC       However, metformin can be used to activate AMPK in muscle and
CC       other cells in culture or ex vivo (PubMed:11602624). Selectively
CC       inhibited by compound C (6-[4-(2-Piperidin-1-yl-ethoxy)-phenyl)]-
CC       3-pyridin-4-yl-pyyrazolo[1,5-a] pyrimidine. Activated by
CC       resveratrol, a natural polyphenol present in red wine, and S17834,
CC       a synthetic polyphenol. Salicylate/aspirin directly activates
CC       kinase activity, primarily by inhibiting Thr-172
CC       dephosphorylation. {ECO:0000269|PubMed:11602624,
CC       ECO:0000269|PubMed:15980064, ECO:0000269|PubMed:21543851,
CC       ECO:0000269|PubMed:22517326}.
CC   -!- SUBUNIT: AMPK is a heterotrimer of an alpha catalytic subunit
CC       (PRKAA1 or PRKAA2), a beta (PRKAB1 or PRKAB2) and a gamma non-
CC       catalytic subunits (PRKAG1, PRKAG2 or PRKAG3). Interacts with
CC       FNIP1 and FNIP2. Associates with internalized insulin
CC       receptor/INSR complexes on Golgi/endosomal membranes; PRKAA2/AMPK2
CC       together with ATIC and HACD3/PTPLAD1 is proposed to be part of a
CC       signaling network regulating INSR autophosphorylation and
CC       endocytosis (PubMed:25687571). {ECO:0000269|PubMed:21543851,
CC       ECO:0000269|PubMed:25687571}.
CC   -!- INTERACTION:
CC       Q9NYB9:ABI2; NbExp=3; IntAct=EBI-1383852, EBI-743598;
CC       Q08117:AES; NbExp=3; IntAct=EBI-1383852, EBI-717810;
CC       Q13155:AIMP2; NbExp=3; IntAct=EBI-1383852, EBI-745226;
CC       Q92624:APPBP2; NbExp=3; IntAct=EBI-1383852, EBI-743771;
CC       Q9NPC3:CCNB1IP1; NbExp=3; IntAct=EBI-1383852, EBI-745269;
CC       Q6FG41:FOS; NbExp=3; IntAct=EBI-1383852, EBI-10198738;
CC       P08151:GLI1; NbExp=3; IntAct=EBI-1383852, EBI-308084;
CC       Q6NT76:HMBOX1; NbExp=3; IntAct=EBI-1383852, EBI-2549423;
CC       Q8IX15-3:HOMEZ; NbExp=3; IntAct=EBI-1383852, EBI-10172004;
CC       Q719H9:KCTD1; NbExp=3; IntAct=EBI-1383852, EBI-9027502;
CC       Q5T7B8-2:KIF24; NbExp=3; IntAct=EBI-1383852, EBI-10213781;
CC       Q9BVG8:KIFC3; NbExp=4; IntAct=EBI-1383852, EBI-2125614;
CC       Q15323:KRT31; NbExp=3; IntAct=EBI-1383852, EBI-948001;
CC       Q96JM7:L3MBTL3; NbExp=3; IntAct=EBI-1383852, EBI-2686809;
CC       H3BTW2:NECAB2; NbExp=3; IntAct=EBI-1383852, EBI-10172876;
CC       Q15233-2:NONO; NbExp=3; IntAct=EBI-1383852, EBI-10203843;
CC       Q7Z3S9:NOTCH2NL; NbExp=3; IntAct=EBI-1383852, EBI-945833;
CC       Q86Y26:NUTM1; NbExp=3; IntAct=EBI-1383852, EBI-10178410;
CC       Q9Y478:PRKAB1; NbExp=3; IntAct=EBI-1383852, EBI-719769;
CC       O43741:PRKAB2; NbExp=11; IntAct=EBI-1383852, EBI-1053424;
CC       P54619:PRKAG1; NbExp=9; IntAct=EBI-1383852, EBI-1181439;
CC       Q93062:RBPMS; NbExp=3; IntAct=EBI-1383852, EBI-740322;
CC       Q8HWS3:RFX6; NbExp=3; IntAct=EBI-1383852, EBI-746118;
CC       P15884:TCF4; NbExp=3; IntAct=EBI-1383852, EBI-533224;
CC       Q15654:TRIP6; NbExp=3; IntAct=EBI-1383852, EBI-742327;
CC       Q9Y3Q8:TSC22D4; NbExp=3; IntAct=EBI-1383852, EBI-739485;
CC       Q8N6Y0:USHBP1; NbExp=3; IntAct=EBI-1383852, EBI-739895;
CC       Q8N1B4:VPS52; NbExp=3; IntAct=EBI-1383852, EBI-2799833;
CC       Q96BR9:ZBTB8A; NbExp=3; IntAct=EBI-1383852, EBI-742740;
CC       Q8NF99:ZNF397; NbExp=3; IntAct=EBI-1383852, EBI-10213894;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000269|PubMed:15866171}. Note=In response to stress,
CC       recruited by p53/TP53 to specific promoters.
CC   -!- DOMAIN: The AIS (autoinhibitory sequence) region shows some
CC       sequence similarity with the ubiquitin-associated domains and
CC       represses kinase activity.
CC   -!- PTM: Ubiquitinated. {ECO:0000250}.
CC   -!- PTM: Phosphorylated at Thr-172 by STK11/LKB1 in complex with
CC       STE20-related adapter-alpha (STRADA) pseudo kinase and CAB39. Also
CC       phosphorylated at Thr-172 by CAMKK2; triggered by a rise in
CC       intracellular calcium ions, without detectable changes in the
CC       AMP/ATP ratio. CAMKK1 can also phosphorylate Thr-172, but at much
CC       lower level. Dephosphorylated by protein phosphatase 2A and 2C
CC       (PP2A and PP2C). Phosphorylated by ULK1; leading to negatively
CC       regulate AMPK activity and suggesting the existence of a
CC       regulatory feedback loop between ULK1 and AMPK. Dephosphorylated
CC       by PPM1A and PPM1B at Thr-172 (mediated by STK11/LKB1).
CC       {ECO:0000269|PubMed:15980064, ECO:0000269|PubMed:21460634}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. SNF1 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U06454; AAA64745.1; -; mRNA.
DR   EMBL; AL035705; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC069680; AAH69680.1; -; mRNA.
DR   EMBL; BC069740; AAH69740.1; -; mRNA.
DR   EMBL; BC069823; AAH69823.1; -; mRNA.
DR   CCDS; CCDS605.1; -.
DR   PIR; S51025; S51025.
DR   RefSeq; NP_006243.2; NM_006252.3.
DR   UniGene; Hs.437039; -.
DR   PDB; 2H6D; X-ray; 1.85 A; A=6-279.
DR   PDB; 2LTU; NMR; -; A=282-339.
DR   PDB; 2YZA; X-ray; 3.02 A; A=6-279.
DR   PDB; 3AQV; X-ray; 2.08 A; A=6-279.
DR   PDB; 4CFE; X-ray; 3.02 A; A/C=1-552.
DR   PDB; 4CFF; X-ray; 3.92 A; A/C=1-552.
DR   PDB; 4ZHX; X-ray; 2.99 A; A/C=2-552.
DR   PDB; 5EZV; X-ray; 2.99 A; A/C=2-347, A/C=397-552.
DR   PDB; 5ISO; X-ray; 2.63 A; A/C=1-552.
DR   PDBsum; 2H6D; -.
DR   PDBsum; 2LTU; -.
DR   PDBsum; 2YZA; -.
DR   PDBsum; 3AQV; -.
DR   PDBsum; 4CFE; -.
DR   PDBsum; 4CFF; -.
DR   PDBsum; 4ZHX; -.
DR   PDBsum; 5EZV; -.
DR   PDBsum; 5ISO; -.
DR   ProteinModelPortal; P54646; -.
DR   SMR; P54646; -.
DR   BioGrid; 111550; 83.
DR   DIP; DIP-39796N; -.
DR   IntAct; P54646; 133.
DR   MINT; MINT-2804161; -.
DR   STRING; 9606.ENSP00000360290; -.
DR   BindingDB; P54646; -.
DR   ChEMBL; CHEMBL2116; -.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   GuidetoPHARMACOLOGY; 1542; -.
DR   iPTMnet; P54646; -.
DR   PhosphoSitePlus; P54646; -.
DR   BioMuta; PRKAA2; -.
DR   DMDM; 20178276; -.
DR   EPD; P54646; -.
DR   MaxQB; P54646; -.
DR   PaxDb; P54646; -.
DR   PeptideAtlas; P54646; -.
DR   PRIDE; P54646; -.
DR   DNASU; 5563; -.
DR   Ensembl; ENST00000371244; ENSP00000360290; ENSG00000162409.
DR   GeneID; 5563; -.
DR   KEGG; hsa:5563; -.
DR   UCSC; uc001cyk.5; human.
DR   CTD; 5563; -.
DR   DisGeNET; 5563; -.
DR   GeneCards; PRKAA2; -.
DR   HGNC; HGNC:9377; PRKAA2.
DR   HPA; HPA044540; -.
DR   MIM; 600497; gene.
DR   neXtProt; NX_P54646; -.
DR   OpenTargets; ENSG00000162409; -.
DR   PharmGKB; PA33745; -.
DR   eggNOG; KOG0586; Eukaryota.
DR   eggNOG; ENOG410XNQ0; LUCA.
DR   GeneTree; ENSGT00870000136390; -.
DR   HOGENOM; HOG000233016; -.
DR   HOVERGEN; HBG050432; -.
DR   KO; K07198; -.
DR   OMA; KALNYEW; -.
DR   PhylomeDB; P54646; -.
DR   TreeFam; TF314032; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-1445148; Translocation of GLUT4 to the plasma membrane.
DR   Reactome; R-HSA-1632852; Macroautophagy.
DR   Reactome; R-HSA-163680; AMPK inhibits chREBP transcriptional activation activity.
DR   Reactome; R-HSA-200425; Import of palmitoyl-CoA into the mitochondrial matrix.
DR   Reactome; R-HSA-2151209; Activation of PPARGC1A (PGC-1alpha) by phosphorylation.
DR   Reactome; R-HSA-380972; Energy dependent regulation of mTOR by LKB1-AMPK.
DR   Reactome; R-HSA-5628897; TP53 Regulates Metabolic Genes.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   SignaLink; P54646; -.
DR   SIGNOR; P54646; -.
DR   ChiTaRS; PRKAA2; human.
DR   EvolutionaryTrace; P54646; -.
DR   GeneWiki; PRKAA2; -.
DR   GenomeRNAi; 5563; -.
DR   PRO; PR:P54646; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000162409; -.
DR   CleanEx; HS_PRKAA2; -.
DR   ExpressionAtlas; P54646; baseline and differential.
DR   Genevisible; P54646; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0031588; C:nucleotide-activated protein kinase complex; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0050405; F:[acetyl-CoA carboxylase] kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047322; F:[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004679; F:AMP-activated protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003682; F:chromatin binding; ISS:UniProtKB.
DR   GO; GO:0035174; F:histone serine kinase activity; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0004712; F:protein serine/threonine/tyrosine kinase activity; IDA:MGI.
DR   GO; GO:0006853; P:carnitine shuttle; TAS:Reactome.
DR   GO; GO:0007050; P:cell cycle arrest; TAS:Reactome.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0042149; P:cellular response to glucose starvation; ISS:UniProtKB.
DR   GO; GO:0031669; P:cellular response to nutrient levels; ISS:UniProtKB.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl.
DR   GO; GO:0006695; P:cholesterol biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0006633; P:fatty acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0055089; P:fatty acid homeostasis; ISS:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0035404; P:histone-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0008610; P:lipid biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0016236; P:macroautophagy; TAS:Reactome.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0032007; P:negative regulation of TOR signaling; ISS:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; ISS:UniProtKB.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; ISS:UniProtKB.
DR   GO; GO:0016239; P:positive regulation of macroautophagy; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:2000505; P:regulation of energy homeostasis; ISS:UniProtKB.
DR   GO; GO:0042304; P:regulation of fatty acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0016241; P:regulation of macroautophagy; ISS:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0014850; P:response to muscle activity; IEA:Ensembl.
DR   GO; GO:0006950; P:response to stress; ISS:UniProtKB.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR032270; AMPK_C.
DR   InterPro; IPR028375; KA1/Ssp2_C.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF16579; AdenylateSensor; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF103243; SSF103243; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Autophagy; Biological rhythms;
KW   Cholesterol biosynthesis; Cholesterol metabolism; Chromatin regulator;
KW   Complete proteome; Cytoplasm; Fatty acid biosynthesis;
KW   Fatty acid metabolism; Kinase; Lipid biosynthesis; Lipid metabolism;
KW   Magnesium; Metal-binding; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Steroid biosynthesis; Steroid metabolism; Sterol biosynthesis;
KW   Sterol metabolism; Transcription; Transcription regulation;
KW   Transferase; Ubl conjugation; Wnt signaling pathway.
FT   CHAIN         1    552       5'-AMP-activated protein kinase catalytic
FT                                subunit alpha-2.
FT                                /FTId=PRO_0000085594.
FT   DOMAIN       16    268       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      22     30       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION      291    376       AIS. {ECO:0000250}.
FT   ACT_SITE    139    139       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      45     45       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     172    172       Phosphothreonine; by LKB1 and CaMKK2.
FT                                {ECO:0000269|PubMed:15980064}.
FT   MOD_RES     258    258       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q09137}.
FT   MOD_RES     377    377       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     491    491       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q09137}.
FT   VARIANT     371    371       P -> T (in breast cancer samples;
FT                                infiltrating ductal carcinoma; somatic
FT                                mutation). {ECO:0000269|PubMed:16959974,
FT                                ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_035623.
FT   VARIANT     407    407       R -> Q (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040355.
FT   VARIANT     523    523       S -> G (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035624.
FT   MUTAGEN     172    172       T->D: Phosphomimetic mutant.
FT   CONFLICT    180    180       A -> T (in Ref. 1; AAA64745).
FT                                {ECO:0000305}.
FT   CONFLICT    271    271       D -> G (in Ref. 1; AAA64745).
FT                                {ECO:0000305}.
FT   CONFLICT    403    404       HL -> RQ (in Ref. 1; AAA64745).
FT                                {ECO:0000305}.
FT   STRAND       16     24       {ECO:0000244|PDB:2H6D}.
FT   STRAND       26     35       {ECO:0000244|PDB:2H6D}.
FT   TURN         36     38       {ECO:0000244|PDB:2H6D}.
FT   STRAND       41     48       {ECO:0000244|PDB:2H6D}.
FT   HELIX        49     54       {ECO:0000244|PDB:2H6D}.
FT   HELIX        58     69       {ECO:0000244|PDB:2H6D}.
FT   STRAND       79     84       {ECO:0000244|PDB:2H6D}.
FT   STRAND       86     94       {ECO:0000244|PDB:2H6D}.
FT   HELIX       101    108       {ECO:0000244|PDB:2H6D}.
FT   HELIX       113    133       {ECO:0000244|PDB:2H6D}.
FT   HELIX       142    144       {ECO:0000244|PDB:2H6D}.
FT   STRAND      145    147       {ECO:0000244|PDB:2H6D}.
FT   STRAND      153    155       {ECO:0000244|PDB:2H6D}.
FT   HELIX       160    162       {ECO:0000244|PDB:2H6D}.
FT   TURN        177    179       {ECO:0000244|PDB:4ZHX}.
FT   HELIX       183    185       {ECO:0000244|PDB:2H6D}.
FT   HELIX       192    209       {ECO:0000244|PDB:2H6D}.
FT   HELIX       219    228       {ECO:0000244|PDB:2H6D}.
FT   HELIX       239    248       {ECO:0000244|PDB:2H6D}.
FT   HELIX       253    255       {ECO:0000244|PDB:2H6D}.
FT   HELIX       259    264       {ECO:0000244|PDB:2H6D}.
FT   HELIX       266    269       {ECO:0000244|PDB:2H6D}.
FT   HELIX       274    276       {ECO:0000244|PDB:2H6D}.
FT   HELIX       283    286       {ECO:0000244|PDB:4ZHX}.
FT   TURN        291    295       {ECO:0000244|PDB:4ZHX}.
FT   HELIX       304    311       {ECO:0000244|PDB:4ZHX}.
FT   HELIX       323    336       {ECO:0000244|PDB:4ZHX}.
FT   HELIX       338    341       {ECO:0000244|PDB:4ZHX}.
FT   STRAND      403    408       {ECO:0000244|PDB:4ZHX}.
FT   HELIX       412    425       {ECO:0000244|PDB:4ZHX}.
FT   STRAND      429    443       {ECO:0000244|PDB:4ZHX}.
FT   TURN        445    447       {ECO:0000244|PDB:4ZHX}.
FT   STRAND      450    460       {ECO:0000244|PDB:4ZHX}.
FT   TURN        461    463       {ECO:0000244|PDB:4ZHX}.
FT   STRAND      464    471       {ECO:0000244|PDB:4ZHX}.
FT   HELIX       535    549       {ECO:0000244|PDB:4ZHX}.
SQ   SEQUENCE   552 AA;  62320 MW;  C46AAFC1D5104975 CRC64;
     MAEKQKHDGR VKIGHYVLGD TLGVGTFGKV KIGEHQLTGH KVAVKILNRQ KIRSLDVVGK
     IKREIQNLKL FRHPHIIKLY QVISTPTDFF MVMEYVSGGE LFDYICKHGR VEEMEARRLF
     QQILSAVDYC HRHMVVHRDL KPENVLLDAH MNAKIADFGL SNMMSDGEFL RTSCGSPNYA
     APEVISGRLY AGPEVDIWSC GVILYALLCG TLPFDDEHVP TLFKKIRGGV FYIPEYLNRS
     VATLLMHMLQ VDPLKRATIK DIREHEWFKQ DLPSYLFPED PSYDANVIDD EAVKEVCEKF
     ECTESEVMNS LYSGDPQDQL AVAYHLIIDN RRIMNQASEF YLASSPPSGS FMDDSAMHIP
     PGLKPHPERM PPLIADSPKA RCPLDALNTT KPKSLAVKKA KWHLGIRSQS KPYDIMAEVY
     RAMKQLDFEW KVVNAYHLRV RRKNPVTGNY VKMSLQLYLV DNRSYLLDFK SIDDEVVEQR
     SGSSTPQRSC SAAGLHRPRS SFDSTTAESH SLSGSLTGSL TGSTLSSVSP RLGSHTMDFF
     EMCASLITTL AR
//
